CN101679340B - 抗肿瘤二氢吡喃-2-酮化合物 - Google Patents

抗肿瘤二氢吡喃-2-酮化合物 Download PDF

Info

Publication number
CN101679340B
CN101679340B CN2007800222645A CN200780022264A CN101679340B CN 101679340 B CN101679340 B CN 101679340B CN 2007800222645 A CN2007800222645 A CN 2007800222645A CN 200780022264 A CN200780022264 A CN 200780022264A CN 101679340 B CN101679340 B CN 101679340B
Authority
CN
China
Prior art keywords
unsubstituted
compound
replacement
hydrogen
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800222645A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679340A (zh
Inventor
玛·赫苏斯·马丁洛佩斯
劳拉·克尔罗莫利纳罗
约瑟·费尔南多·雷耶斯贝尼特斯
阿尔贝托·罗德瑞谷兹维肯特
玛丽亚·佳兰佐加西亚-艾巴罗拉
卡门·莫西亚佩雷兹
安德烈斯·弗兰切斯基索洛索
弗朗西斯科·杉切兹杉楚
玛丽亚·德尔卡门·奎瓦斯马昌特
罗格利奥·费尔南德斯罗德里库斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN101679340A publication Critical patent/CN101679340A/zh
Application granted granted Critical
Publication of CN101679340B publication Critical patent/CN101679340B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2007800222645A 2006-06-16 2007-06-15 抗肿瘤二氢吡喃-2-酮化合物 Expired - Fee Related CN101679340B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380173.2 2006-06-16
EP06380173 2006-06-16
PCT/EP2007/055959 WO2007144423A1 (en) 2006-06-16 2007-06-15 Antitumoral dihydropyran-2-one compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011102036625A Division CN102336730A (zh) 2006-06-16 2007-06-15 抗肿瘤二羟基吡喃-2-酮化合物

Publications (2)

Publication Number Publication Date
CN101679340A CN101679340A (zh) 2010-03-24
CN101679340B true CN101679340B (zh) 2013-06-05

Family

ID=38508885

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800222645A Expired - Fee Related CN101679340B (zh) 2006-06-16 2007-06-15 抗肿瘤二氢吡喃-2-酮化合物
CN2011102036625A Pending CN102336730A (zh) 2006-06-16 2007-06-15 抗肿瘤二羟基吡喃-2-酮化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011102036625A Pending CN102336730A (zh) 2006-06-16 2007-06-15 抗肿瘤二羟基吡喃-2-酮化合物

Country Status (29)

Country Link
US (2) US8324406B2 (https=)
EP (3) EP2404912A3 (https=)
JP (2) JP5117491B2 (https=)
KR (1) KR101474031B1 (https=)
CN (2) CN101679340B (https=)
AR (1) AR061506A1 (https=)
AT (1) ATE522514T1 (https=)
AU (1) AU2007259257B8 (https=)
BR (2) BRPI0722429A2 (https=)
CA (1) CA2654334C (https=)
CY (1) CY1112103T1 (https=)
DK (1) DK2032551T3 (https=)
ES (1) ES2371942T3 (https=)
HR (1) HRP20110845T1 (https=)
IL (1) IL195676A (https=)
MX (1) MX2008015754A (https=)
MY (1) MY145788A (https=)
NO (2) NO341508B1 (https=)
NZ (1) NZ573706A (https=)
PL (1) PL2032551T3 (https=)
PT (1) PT2032551E (https=)
RS (1) RS52034B (https=)
RU (2) RU2444519C2 (https=)
SG (1) SG174830A1 (https=)
SI (1) SI2032551T1 (https=)
TW (2) TWI373469B (https=)
UA (1) UA97369C2 (https=)
WO (1) WO2007144423A1 (https=)
ZA (1) ZA200810315B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2231633E (pt) * 2007-12-20 2014-01-20 Pharma Mar Sa Compostos antitumorais
ES2411930T3 (es) 2008-02-20 2013-07-09 Actelion Pharmaceuticals Ltd. Compuestos antibióticos azatricíclicos
RU2501799C2 (ru) 2008-02-22 2013-12-20 Актелион Фармасьютикалз Лтд Поизводные оксазолидинона
BRPI0920895A8 (pt) 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
KR101667066B1 (ko) 2008-10-10 2016-10-17 액테리온 파마슈티칼 리미티드 옥사졸리디닐 항생제
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
CN110790737B (zh) * 2019-11-07 2022-07-22 河南中烟工业有限责任公司 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法
CN118139851A (zh) 2021-10-22 2024-06-04 法马马有限公司 抗肿瘤化合物
CN117510448A (zh) * 2023-11-13 2024-02-06 贵州中医药大学 一种二氢吡喃酮衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kuhnt M et al.Microbial Conversion Products of Leptomycin B.《Applied and Environmental Microbiology》.1998,第64卷(第2期),全文. *

Also Published As

Publication number Publication date
JP5117491B2 (ja) 2013-01-16
NZ573706A (en) 2011-09-30
US20120190870A1 (en) 2012-07-26
RU2011133128A (ru) 2013-02-10
ATE522514T1 (de) 2011-09-15
JP2012021023A (ja) 2012-02-02
JP2009539943A (ja) 2009-11-19
UA97369C2 (ru) 2012-02-10
KR20090024261A (ko) 2009-03-06
MY145788A (en) 2012-04-30
NO20090054L (no) 2009-01-06
IL195676A0 (en) 2009-09-01
ZA200810315B (en) 2010-02-24
AU2007259257B2 (en) 2011-12-08
SG174830A1 (en) 2011-10-28
NO20111248L (no) 2008-12-16
WO2007144423A1 (en) 2007-12-21
EP2404912A3 (en) 2012-07-25
DK2032551T3 (da) 2012-01-02
BRPI0713031A2 (pt) 2013-03-12
US20090186938A1 (en) 2009-07-23
BRPI0722429A2 (pt) 2013-11-26
AU2007259257B8 (en) 2012-04-05
RS52034B (sr) 2012-04-30
RU2009101150A (ru) 2010-07-27
KR101474031B1 (ko) 2014-12-17
US8501968B2 (en) 2013-08-06
CA2654334A1 (en) 2007-12-21
CN102336730A (zh) 2012-02-01
AU2007259257A8 (en) 2012-04-05
CY1112103T1 (el) 2015-11-04
BRPI0713031B1 (pt) 2020-10-06
PL2032551T3 (pl) 2012-01-31
EP2404913A3 (en) 2012-06-06
HRP20110845T1 (hr) 2011-12-31
ES2371942T3 (es) 2012-01-11
EP2032551B9 (en) 2012-02-29
SI2032551T1 (sl) 2012-01-31
TW201213316A (en) 2012-04-01
PT2032551E (pt) 2011-12-06
NO341508B1 (no) 2017-11-27
IL195676A (en) 2012-06-28
AU2007259257A1 (en) 2007-12-21
BRPI0713031B8 (pt) 2021-05-25
TWI373469B (en) 2012-10-01
US20100048690A2 (en) 2010-02-25
HK1130052A1 (en) 2009-12-18
MX2008015754A (es) 2009-01-12
EP2032551B1 (en) 2011-08-31
CA2654334C (en) 2014-06-10
CN101679340A (zh) 2010-03-24
RU2444519C2 (ru) 2012-03-10
AR061506A1 (es) 2008-09-03
EP2404913A2 (en) 2012-01-11
EP2404912A2 (en) 2012-01-11
EP2032551A1 (en) 2009-03-11
US8324406B2 (en) 2012-12-04
TW200811128A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
CN101679340B (zh) 抗肿瘤二氢吡喃-2-酮化合物
CN102190643B (zh) 抗肿瘤化合物
HK1130052B (en) Antitumoral dihydropyran-2-one compounds
AU2011203085A1 (en) Antitumoral dihydropyran-2-one compounds
HK1147998B (en) Antitumoral compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: PHARMA MAR, S. A.

Free format text: FORMER NAME: PHARMA MAR S. A. U.

CP01 Change in the name or title of a patent holder

Address after: Madrid

Patentee after: PHARMA MAR, S.A.

Address before: Madrid

Patentee before: PHARMA MAR, S.A.U.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130605

CF01 Termination of patent right due to non-payment of annual fee